KemPharm hammered after FDA panel

KemPharm Inc. (NASDAQ:KMPH) sank $8.76 (56%) to $6.91 on Friday, a day after FDA advisory committees voted against labeling analgesic Apadaz benzhydrocodone/acetaminophen as an abuse deterrent product. The committees did vote in favor of Apadaz's approval for short-term management of acute pain (see BioCentury Extra, May 5). ...